INT119080

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 8.88
Pain Relevance 0.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular matrix organization (PTK2) embryo development (PTK2) microtubule organizing center (PTK2)
cytoplasm (PTK2) signal transducer activity (PTK2) cytosol (PTK2)
Anatomy Link Frequency
AsPC-1 2
PTK2 (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 4 74.16 Quite High
peripheral neuropathy 2 71.76 Quite High
positron emission tomography 4 52.88 Quite High
aspirin 3 50.00 Quite Low
Bioavailability 1 26.00 Quite Low
palliative 13 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
cINOD 2 5.00 Very Low Very Low Very Low
agonist 1 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pancreatic Cancer 579 99.30 Very High Very High Very High
Cancer 337 98.44 Very High Very High Very High
Apoptosis 445 98.24 Very High Very High Very High
Solid Tumor 6 93.52 High High
Metastasis 78 88.76 High High
Adhesions 91 88.68 High High
Cytomegalovirus Infection 12 87.08 High High
Skin Cancer 31 86.40 High High
Breast Cancer 12 85.84 High High
Colon Cancer 6 81.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
PF-562,271 is a potent inhibitor of both FAK and the related kinase Pyk2, while TAE226 is an effective inhibitor of both FAK and insulin-like growth factor I receptor [38].
Negative_regulation (inhibitor) of FAK
1) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.59 Pain Relevance 0
PF-562,271 is a potent inhibitor of both FAK and the related kinase Pyk2, while TAE226 is an effective inhibitor of both FAK and insulin-like growth factor I receptor [38].
Negative_regulation (inhibitor) of FAK
2) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.59 Pain Relevance 0
The RNAi vectors (FAK RNAi1, FAK RNAi2) were generated by ligating the annealed DNA oligos into the linearized vector and used to inhibit human FAK gene (GenBank: NM_153831.2).
Negative_regulation (inhibit) of FAK
3) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.14 Pain Relevance 0
It further confirms the role of constitutive FAK phosphorylation in the intrinsic chemoresistance to Gem in pancreatic cancer cells and indicates development of selective FAK phosphorylation inhibitors may be a promising way to enhance chemosensitivity in pancreatic cancer.
Negative_regulation (inhibitors) of FAK associated with pancreatic cancer
4) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.91 Pain Relevance 0
PF-228, a novel FAK inhibitor, has become available recently.
Negative_regulation (inhibitor) of FAK
5) Confidence 0.56 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.42 Pain Relevance 0
Compared with nontransfection and vector-transfection controls, transient transfection of RNAi plasmids (FAK RNAi1 and FAK RNAi2) resulted in downregulation of FAK protein levels and subsequent reduction of pFAK (pY397) levels (Fig. 3A), whereas transfection of pcDNA3.1-FRNK plasmid decreased pFAK levels without changing total FAK expression (Fig. 3B).
Negative_regulation (downregulation) of FAK
6) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.08 Pain Relevance 0
Development of selective FAK phosphorylation inhibitors may be a promising way to enhance chemosensitivity in pancreatic cancer.



Negative_regulation (inhibitors) of FAK associated with pancreatic cancer
7) Confidence 0.41 Published 2009 Journal Mol Cancer Section Abstract Doc Link PMC2806309 Disease Relevance 0.45 Pain Relevance 0
Our results suggest that FAK can be an attractive therapeutic target for pancreatic cancer, and the development of selective FAK phosphorylation inhibitors may be a promising way to enhance Gem chemosensitivity in pancreatic cancer.


Negative_regulation (inhibitors) of FAK associated with pancreatic cancer
8) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.74 Pain Relevance 0
Moreover, inhibition of constitutive FAK phosphorylation in Panc-1 cells and LN-induced FAK phosphorylation in AsPC-1 cells by a novel and more specific FAK phosphorylation inhibitor PF-573,228 showed similar results with those of FAK phosphorylation inhibition by FAK RNAi or FRNK overexpression.


Negative_regulation (inhibition) of FAK in AsPC-1
9) Confidence 0.41 Published 2009 Journal Mol Cancer Section Abstract Doc Link PMC2806309 Disease Relevance 0.45 Pain Relevance 0
The C-terminal non-catalytic domain of FAK termed FRNK functions as a competitive inhibitor of FAK and ectopic expression of FRNK specifically inhibits FAK autophosphorylation at Tyr397 and thus attenuates its activity [19,20].
Negative_regulation (inhibitor) of FAK
10) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.58 Pain Relevance 0
Our studies found that LN induced FAK phosphorylation in a time-dependent manner in AsPC-1 cells, and FAK phosphorylation inhibition by either RNAi or FRNK overexpression antagonized the effect of LN on Gem chemoresistance.
Negative_regulation (inhibition) of FAK in AsPC-1
11) Confidence 0.41 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.82 Pain Relevance 0
Compared with nontransfection and vector-transfection controls, transient transfection of RNAi plasmids (FAK RNAi1 and FAK RNAi2) resulted in downregulation of FAK protein levels and subsequent reduction of pFAK (pY397) levels (Fig. 3A), whereas transfection of pcDNA3.1-FRNK plasmid decreased pFAK levels without changing total FAK expression (Fig. 3B).
Negative_regulation (reduction) of pFAK
12) Confidence 0.36 Published 2009 Journal Mol Cancer Section Body Doc Link PMC2806309 Disease Relevance 0.08 Pain Relevance 0
PF-00562271 is an oral reversible inhibitor of FAK, and phase I results for this drug were presented [28].
Negative_regulation (inhibitor) of FAK
13) Confidence 0.30 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2647552 Disease Relevance 1.86 Pain Relevance 0.23
Overall, an inverse relationship was noted between FAK and E-cadherin expression (Additional File 3: A).
Negative_regulation (noted) of FAK
14) Confidence 0.18 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 1.18 Pain Relevance 0
This was accompanied by a decrease in the expressions of SOS and phosphorylated MAP kinases, ERK1 and ERK2, but not FAK or Grab2.
Negative_regulation (decrease) of FAK
15) Confidence 0.14 Published 2004 Journal Med. Sci. Monit. Section Body Doc Link 15173663 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox